Logo.png
QHSLab, Inc. (USAQ) Reports Third Quarter Financial Results
14 nov. 2023 08h30 HE | QHSLab, Inc.
25% Y-O-Y Revenue Growth in Q3 2023 Compared to Q3 2022 and 51% Increase in Gross Profit.  ●In Q3 2023, QHSLab generated $336,407 in revenues, reflecting a notable 25% year-over-year increase from...
BMTM-logo-retina.jpg
Bright Mountain Media, Inc Announces Third Quarter Financial Results - Updated
14 nov. 2022 15h58 HE | Bright Mountain Media, Inc.
Successful third quarter coupled with revenue growth Revenue increased 38% to $5.2 million compared to the third quarter 2021.Gross margin was $2.1 million growing 2% as compared to the third...
BMTM-logo-retina.jpg
Bright Mountain Media, Inc Announces Third Quarter Financial Results
14 nov. 2022 08h25 HE | Bright Mountain Media, Inc.
Successful third quarter coupled with revenue growth  ■Revenue increased 38% to $5.2 million compared to the third quarter 2021.     ■Gross margin was $2.1 million growing 2% as compared to the...
Logo.jpg
Worksport Reports 2021 Third Quarter Financial Results and Provides Business Update
15 nov. 2021 10h16 HE | Worksport Ltd
Mississauga, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Worksport Ltd (Nasdaq-CM: WKSP) (the “Company”) reported financial results for the 2021 third quarter period ended September 30, 2021. Investors are...
Logo.png
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development Programs and Milestones
15 nov. 2021 08h00 HE | Cocrystal Pharma, Inc.
Submitted pre-IND briefing package to the FDA for intranasal/pulmonary CDI-45205 for the treatment of COVID-19 and sets goal of initiating IND-enabling study and Phase 1 in 2022Advance oral COVID-19...
Image 1.jpg
mPhase Technologies Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
19 mai 2021 08h30 HE | mPhase Technologies, Inc.
Company Reports Fifth Consecutive Quarter of Profitability; Fortifies Balance Sheet to Pursue 5G and EV Charging Opportunities Gaithersburg, MD, May 19, 2021 (GLOBE NEWSWIRE) -- mPhase...
logo.png
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
07 nov. 2019 07h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Phase 3 “RESOLVE-1” study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in...
MamaMancini's logo
MamaMancini’s Reports Fiscal 2019 Third Quarter Financial Results
11 déc. 2018 16h15 HE | MamaMancini's Holdings, Inc.
Record Sales and Net Income in Q3 Q3 Revenue Up 12%; $8.2 million vs. $7.4 millionOperating Income More Than Doubles to $536,000 vs. $258,000Net Income Up 12x to $356,000 vs. Net Income of $29,000Cash...